Ultragenyx — Sr. Director, Digital Clinical Development.
Senior clinical development technology leadership across Global Development Operations, protocol feasibility, endpoint strategy, operational risk, patient-centered UI/UX, wearables, CGM, Rarify, Innovation Lab, and live study execution.
Global Development Operations
Worked inside Global Development Operations under an SVP reporting to the CMO, connecting digital clinical development to the clinical operating structure of the company.
Operations and Strategic Leadership
Served as a member of the Operations Leadership Team and Strategic Leadership Team for clinical operations technology, digital endpoints, and study execution readiness.
Protocol Development Teams
Represented technology feasibility in relation to endpoint strategy, operational risk identification and mitigation, patient-centered UI/UX, wearable strategy, and practical execution.
Wearables and CGM SME
Served as company SME for wearables, especially CGM, across multiple programs including gene therapy and metabolic disease.
Rarify in pivotal development
Rarify was live in support of primary endpoints in a global pivotal Phase III clinical trial in EMEA, connecting patient/site collaboration, metabolic monitoring workflows, device logistics, and regulated clinical data capture.
Inspection-ready execution
The work combined Computer Software Assurance, QA-controlled delivery, workflow design, and clinical operations support for systems used inside active studies.
Clinical Development Leadership
Protocol Development Teams, OLT/SLT membership, endpoint strategy, operational risk, UI/UX, and wearables/CGM SME scope.
Innovation Lab
Global clinical technology delivery engine built from zero to 54 people across engineering, QA, product, test, study management, logistics, and clinical operations support.
Request access to selected supporting materials
Selected source documents, summaries, and supporting materials may be available for appropriate professional discussions.